| Jason Michael Hope, MD | |
|
30 Page St, Pinehurst, NC 28374 | |
| (910) 687-4188 | |
| (910) 235-0171 |
| Full Name | Jason Michael Hope |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 17 Years |
| Location | 30 Page St, Pinehurst, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720286453 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZC0500X | Pathology - Cytopathology | LL30045 (South Carolina) | Secondary |
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | LL30045 (South Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Marlboro Chesterfield Pathology, Pc | 4486546819 | 10 |
| Pinehurst Surgical Clinic Pa | 4587561394 | 98 |
| Premier Gastroenterology Pa | 5890787006 | 20 |
| Pinehurst Medical Clinic Inc | 5991617169 | 159 |
| Atlantic Gastroenterology Pa | 6507897022 | 9 |
| Coastal Carolina Health Care Pa | 9739087693 | 111 |
News Archive
A new study funded by U.S. National Institute for Occupational Safety and Health reports that foreign-born workers reported a lower rate of non-fatal work-related injuries than U.S.-born workers, based on data collected from the National Health Interview Survey from 1997 to 2005.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.
Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.
› Verified 6 days ago
| Entity Name | Pinehurst Medical Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255388369 PECOS PAC ID: 5991617169 Enrollment ID: O20031105000305 |
News Archive
A new study funded by U.S. National Institute for Occupational Safety and Health reports that foreign-born workers reported a lower rate of non-fatal work-related injuries than U.S.-born workers, based on data collected from the National Health Interview Survey from 1997 to 2005.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.
Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.
› Verified 6 days ago
| Entity Name | Eagle Physicians And Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457436982 PECOS PAC ID: 0244134468 Enrollment ID: O20031120000436 |
News Archive
A new study funded by U.S. National Institute for Occupational Safety and Health reports that foreign-born workers reported a lower rate of non-fatal work-related injuries than U.S.-born workers, based on data collected from the National Health Interview Survey from 1997 to 2005.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.
Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.
› Verified 6 days ago
| Entity Name | Pinehurst Surgical Clinic Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962434324 PECOS PAC ID: 4587561394 Enrollment ID: O20031218000239 |
News Archive
A new study funded by U.S. National Institute for Occupational Safety and Health reports that foreign-born workers reported a lower rate of non-fatal work-related injuries than U.S.-born workers, based on data collected from the National Health Interview Survey from 1997 to 2005.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.
Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.
› Verified 6 days ago
| Entity Name | Coastal Carolina Health Care Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780623207 PECOS PAC ID: 9739087693 Enrollment ID: O20031230000224 |
News Archive
A new study funded by U.S. National Institute for Occupational Safety and Health reports that foreign-born workers reported a lower rate of non-fatal work-related injuries than U.S.-born workers, based on data collected from the National Health Interview Survey from 1997 to 2005.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.
Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.
› Verified 6 days ago
| Entity Name | Wilmington Gastroenterology Associates, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922040419 PECOS PAC ID: 2163315672 Enrollment ID: O20040206000443 |
News Archive
A new study funded by U.S. National Institute for Occupational Safety and Health reports that foreign-born workers reported a lower rate of non-fatal work-related injuries than U.S.-born workers, based on data collected from the National Health Interview Survey from 1997 to 2005.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.
Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.
› Verified 6 days ago
| Entity Name | Premier Gastroenterology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952306599 PECOS PAC ID: 5890787006 Enrollment ID: O20040330001364 |
News Archive
A new study funded by U.S. National Institute for Occupational Safety and Health reports that foreign-born workers reported a lower rate of non-fatal work-related injuries than U.S.-born workers, based on data collected from the National Health Interview Survey from 1997 to 2005.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.
Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.
› Verified 6 days ago
| Entity Name | Fayetteville Associates In Laboratory Medicine Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295793594 PECOS PAC ID: 8224090675 Enrollment ID: O20041028000861 |
News Archive
A new study funded by U.S. National Institute for Occupational Safety and Health reports that foreign-born workers reported a lower rate of non-fatal work-related injuries than U.S.-born workers, based on data collected from the National Health Interview Survey from 1997 to 2005.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.
Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.
› Verified 6 days ago
| Entity Name | Atlantic Gastroenterology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740238435 PECOS PAC ID: 6507897022 Enrollment ID: O20050824001057 |
News Archive
A new study funded by U.S. National Institute for Occupational Safety and Health reports that foreign-born workers reported a lower rate of non-fatal work-related injuries than U.S.-born workers, based on data collected from the National Health Interview Survey from 1997 to 2005.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.
Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.
› Verified 6 days ago
| Entity Name | Marlboro Chesterfield Pathology, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619953965 PECOS PAC ID: 4486546819 Enrollment ID: O20050929000695 |
News Archive
A new study funded by U.S. National Institute for Occupational Safety and Health reports that foreign-born workers reported a lower rate of non-fatal work-related injuries than U.S.-born workers, based on data collected from the National Health Interview Survey from 1997 to 2005.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.
Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason Michael Hope, MD Po Box 4270, Pinehurst, NC 28374-4270 Ph: (910) 687-4188 | Jason Michael Hope, MD 30 Page St, Pinehurst, NC 28374 Ph: (910) 687-4188 |
News Archive
A new study funded by U.S. National Institute for Occupational Safety and Health reports that foreign-born workers reported a lower rate of non-fatal work-related injuries than U.S.-born workers, based on data collected from the National Health Interview Survey from 1997 to 2005.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.
RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.
Physicians treating patients with epilepsy are in a difficult legal situation when they have to assess their patients' ability to drive. In the current edition of the Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[13]: 217-23), the occupational physician Monika Gube and her coauthors describe the problems, using an individual case as an example.
› Verified 6 days ago
Dr. Chad Richard Rund, DO Pathology Medicare: Accepting Medicare Assignments Practice Location: 30 Page St, Pinehurst, NC 28374 Phone: 910-687-4188 Fax: 910-235-0171 | |
Dr. James Andrew Winter, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 155 Memorial Dr, Pinehurst, NC 28374 Phone: 910-215-1156 Fax: 910-215-1944 | |
Dr. Charles Carr Schirmer, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 155 Memorial Dr, Pinehurst, NC 28374 Phone: 910-215-1930 Fax: 910-215-1151 | |
Huankai Hu, MD, PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 30 Page St., Pinehurst, NC 28374 Phone: 843-479-2402 Fax: 843-479-6609 | |
Dell Andrew Dembosky, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 30 Page St., Pinehurst, NC 28374 Phone: 910-687-4188 Fax: 843-479-6609 | |
Dr. Junwei Chen, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 30 Page St, Pinehurst, NC 28374 Phone: 910-687-4188 |